DE69601158T2 - Zusammensetzungen enthaltend nsaid-nanopartikel - Google Patents

Zusammensetzungen enthaltend nsaid-nanopartikel

Info

Publication number
DE69601158T2
DE69601158T2 DE69601158T DE69601158T DE69601158T2 DE 69601158 T2 DE69601158 T2 DE 69601158T2 DE 69601158 T DE69601158 T DE 69601158T DE 69601158 T DE69601158 T DE 69601158T DE 69601158 T2 DE69601158 T2 DE 69601158T2
Authority
DE
Germany
Prior art keywords
compositions containing
nanoparticles
containing nsaid
nsaid nanoparticles
maintain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69601158T
Other languages
English (en)
Other versions
DE69601158D1 (de
Inventor
W Eickhoff
David Engers
Karl Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanosystems LLC
Original Assignee
Nanosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems LLC filed Critical Nanosystems LLC
Publication of DE69601158D1 publication Critical patent/DE69601158D1/de
Application granted granted Critical
Publication of DE69601158T2 publication Critical patent/DE69601158T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
DE69601158T 1995-02-09 1996-01-18 Zusammensetzungen enthaltend nsaid-nanopartikel Expired - Lifetime DE69601158T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/385,614 US5518738A (en) 1995-02-09 1995-02-09 Nanoparticulate nsaid compositions
PCT/US1996/000797 WO1996024339A1 (en) 1995-02-09 1996-01-18 Compositions comprising nanoparticles of nsaid

Publications (2)

Publication Number Publication Date
DE69601158D1 DE69601158D1 (de) 1999-01-28
DE69601158T2 true DE69601158T2 (de) 1999-07-22

Family

ID=23522150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69601158T Expired - Lifetime DE69601158T2 (de) 1995-02-09 1996-01-18 Zusammensetzungen enthaltend nsaid-nanopartikel

Country Status (10)

Country Link
US (1) US5518738A (de)
EP (1) EP0808156B1 (de)
JP (1) JP3710818B2 (de)
AT (1) ATE174506T1 (de)
AU (1) AU4900996A (de)
CA (1) CA2212779C (de)
DE (1) DE69601158T2 (de)
DK (1) DK0808156T3 (de)
ES (1) ES2125099T3 (de)
WO (1) WO1996024339A1 (de)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (de) * 1995-02-24 2004-08-25 Elan Pharma International Limited Nanopartikel-dispersionen enthaltende aerosole
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9726543D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel compositions
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP2266542A3 (de) * 1998-10-01 2013-07-31 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
CN100413881C (zh) * 1999-12-08 2008-08-27 法马西亚公司 依匹乐酮晶形
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
DK1413331T3 (da) * 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
WO2003000228A2 (en) * 2001-06-22 2003-01-03 Elan Pharma International Ltd. Method for high through put screening using a small scale mill or microfluidics
US6596708B1 (en) 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
EP1429772A1 (de) * 2001-09-25 2004-06-23 Pharmacia Corporation N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazol
EP1429749A2 (de) * 2001-09-26 2004-06-23 Baxter International Inc. Herstellung von nanopartikeln im submikrometerbereich durch dispersion und entzug des lösungsmittels oder der flüssigen phase
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
WO2003034302A1 (fr) * 2001-10-15 2003-04-24 Stark Co., Ltd. Serveur de fourniture de contenu et systeme de fourniture de contenu dote d'un tel serveur
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
AU2003210517A1 (en) * 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
AU2003217791A1 (en) * 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
EP1490030B2 (de) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanopartikelzusammensetzungen von angiogeneseinhibitoren
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
ES2380318T3 (es) 2002-04-12 2012-05-10 Alkermes Pharma Ireland Limited Formulaciones nanoparticulares de megestrol
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP1503737B1 (de) * 2002-05-06 2009-01-07 Elan Pharma International Limited Nystatin-nanopartikelzusammensetzungen
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
KR100493449B1 (ko) * 2002-05-28 2005-06-07 한국화학연구원 화장품 재료로 사용되는 나노입자의 표면 코팅 방법
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
RU2005103625A (ru) * 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
DK1553927T3 (da) * 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
ES2365012T3 (es) * 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1626742A1 (de) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilisierung von dispersionen von nanopartikulären aktiven stoffen mittels gamma-strahlung
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
US6943131B1 (en) * 2004-03-02 2005-09-13 Saudi Basic Industries Corporation Selective zeolite catalyst modification
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
AU2005269800B8 (en) 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
EP1853234A2 (de) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol und injizierbare formulierungen aus benzodiazepin in form von nanoteilchen
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
CN101198316A (zh) * 2005-03-17 2008-06-11 伊兰制药国际有限公司 纳米微粒双膦酸盐组合物
MX2007011772A (es) * 2005-03-23 2007-12-05 Elan Pharma Int Ltd Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
JP2008535921A (ja) * 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド シクロスポリンを含むナノ粒子および放出調節された組成物
CA2607494A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CA2610448A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
EP1898882B1 (de) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanopartikuläre ebastinformulierungen
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
KR20080080119A (ko) * 2005-11-15 2008-09-02 백스터 인터내셔널 인코포레이티드 리폭시게나제 억제제의 조성물
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
NZ573555A (en) * 2006-05-30 2012-09-28 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
KR20100052262A (ko) * 2008-11-10 2010-05-19 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
SG10201401700XA (en) 2009-04-24 2014-06-27 Iceutica Pty Ltd A novel formulation of diclofenac
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
EP2560624B1 (de) 2010-04-23 2018-07-04 KemPharm, Inc. Therapeutische formulierung für reduzierte medikamenten-nebenwirkungen
WO2013016174A1 (en) 2011-07-22 2013-01-31 Chemocentryx, Inc. A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
JP6166721B2 (ja) 2011-07-22 2017-07-19 ケモセントリックス， インコーポレイテッド ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の多形
CN103906744A (zh) 2011-09-01 2014-07-02 葛兰素集团有限公司 新晶型
CN103957888B (zh) 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
WO2013059676A1 (en) 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
DE102014001420B4 (de) 2014-02-03 2020-04-09 Protec Polymer Processing Gmbh Dosieranlage zur Dosierung von Schüttgütern, Kunststoffverarbeitungsanlage und Verfahren zur Dosierung von Schüttgütern
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
IN2014CH01872A (de) 2014-04-09 2015-05-08 Nanoceutica Lab Pvt Ltd
CR20160598A (es) 2014-06-25 2017-03-10 Glaxosmithkline Intelectual Property Dev Ltd Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida
JP2017527574A (ja) 2014-09-08 2017-09-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−（４−（４−エトキシ−６−オキソ−１，６−ジヒドロピリジン−３−イル）−２−フルオロフェニル）−ｎ−（５−（１，１，１−トリフルオロ−２−メチルプロパン−２−イル）イソオキサゾール−３−イル）アセトアミドの結晶形
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EP3288957A4 (de) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. Nukleosidanaloga zur behandlung von viren der flaviviidae-familie und krebs
CN105241793B (zh) * 2015-09-07 2016-10-26 国家纳米科学中心 一种载药胶束形态粒径的测定方法
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607662D0 (en) * 1986-03-27 1986-04-30 Rainsford K D Pharmaceutical formulation
AU633507B2 (en) * 1988-08-02 1993-02-04 London Biotechnology Limited An amplification assay for hydrolase enzymes
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
NZ234587A (en) * 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5183829A (en) * 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
ATE150297T1 (de) * 1992-06-10 1997-04-15 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln

Also Published As

Publication number Publication date
DE69601158D1 (de) 1999-01-28
JP3710818B2 (ja) 2005-10-26
JPH10513198A (ja) 1998-12-15
ES2125099T3 (es) 1999-02-16
CA2212779A1 (en) 1996-08-15
WO1996024339A1 (en) 1996-08-15
DK0808156T3 (da) 1999-08-23
ATE174506T1 (de) 1999-01-15
EP0808156A1 (de) 1997-11-26
CA2212779C (en) 2003-05-06
AU4900996A (en) 1996-08-27
US5518738A (en) 1996-05-21
EP0808156B1 (de) 1998-12-16

Similar Documents

Publication Publication Date Title
DE69601158T2 (de) Zusammensetzungen enthaltend nsaid-nanopartikel
DK0644755T3 (da) Overflademodificerede NSAID-nanopartikler
AU3731699A (en) Orally disintegrable tablets
CA2348451A1 (en) Dosage forms containing taste masked active agents
DE69626116D1 (de) Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
CA2504489A1 (en) Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
UA27899C2 (uk) Порошкова антибактеріальна композиція, що призначена для орального використання, яка містить гідратований цефтибутен
ATE127010T1 (de) Zahnpasten gegen zahnstein.
FI910088A (fi) Oral farmaceutisk komposition.
ATE187334T1 (de) Pharmazeutische zusammensetzung in form eines gels mit chondroitinsulfat in salzform zur oralen verabreichung
IT1250658B (it) Composizioni farmaceutiche utilizzabili in gastroenterologia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition